Karyopharm Therapeutics
KPTI
80 hedge funds and large institutions have $345M invested in Karyopharm Therapeutics in 2017 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 22 reducing their positions, and 13 closing their positions.
158% more call options, than puts
Call options by funds: $2.04M | Put options by funds: $790K
44% more capital invested
Capital invested by funds: $239M → $345M (+$105M)
41% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 22
0.15% more ownership
Funds ownership: 4.12% → 4.27% (+0.15%)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
7% less funds holding
Funds holding: 86 → 80 (-6)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$26.8M |
| 2 |
TA
Teachers Advisors
New York
|
+$4.06M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
+$3.64M |
| 4 |
IHM
Iguana Healthcare Management
New York
|
+$2.94M |
| 5 |
EI
EAM Investors
Solana Beach,
California
|
+$2.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$4.84M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.34M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$2.33M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$987K |
| 5 |
Franklin Resources
San Mateo,
California
|
-$887K |
KPTI Hedge Fund Activity: Q1 2017 in Review
80 of the 4,018 institutional investors tracked by Wall St. Rank reported a position in Karyopharm Therapeutics (KPTI) for Q1 2017, worth a combined $345M — up 44% from $239M a quarter earlier.
Fund positioning in KPTI was balanced in Q1 2017: 13 funds opened new positions, 13 closed out, 31 added to existing stakes and 22 trimmed.
The largest buyer was BlackRock, adding an estimated $26.8M. The largest seller was Millennium Management, cutting an estimated $4.84M.
- 80 institutional investors held Karyopharm Therapeutics (KPTI) as of Q1 2017, down from 86 in Q4 2016.
- Funds reported $345M of Karyopharm Therapeutics stock for Q1 2017, up 44% quarter-over-quarter.
- 13 funds opened new Karyopharm Therapeutics positions in Q1 2017 and 13 closed out, a net change of 0 holders.
- The largest Karyopharm Therapeutics buyer in Q1 2017 was BlackRock, an estimated $26.8M added.
- The largest Karyopharm Therapeutics seller in Q1 2017 was Millennium Management, an estimated $4.84M sold.
Based on aggregated 13F filings for Q1 2017.